Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Clinical Lab Market In China Booming Despite Recession
Diagnostic companies looking for growth in a tough economy can still find a vibrant market for their products in China, says a leading healthcare market research publisher. IVD markets in China will grow to more than $1.5 billion in 2009, making it the world"s sixth largest IVD market. The last few years have seen market growth of 15-20%. With about 575 new hospitals opening each year and a government plan to open more than 20,000 health clinics, the lab market is booming, according to a new report, "Who is Who in Clinical Diagnostics in China (Manufacturers and Distributors Profiles, Market, Industry Overview)," from Kalorama Information, in partnership with IVD market research firm McEvoy & Farmer.
generic viagra online
GlaxoSmithKline Pledges $97M Investment In AIDS Drugs For Africa, Allows South African Drugmaker To Produce Generic Second-Line Treatment
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports. GSK also put forth "a new free voluntary licensing agreement for AIDS drug abacavir, or Ziagen with South African generic drugmaker Aspen Pharmacare." According to Reuters, Aspen will be able to "manufacture a cheaper generic version of the drug."
News of the day
1/4 Of Patients On Highest Investigational Doses Of CP-690,550 Achieve ACR70 At Week 12
A quarter of active rheumatoid arthritis (RA) patients receiving either 10mg (24.6%) or 15mg (28.1%) twice daily of the investigational oral JAK-3 (janus-associated kinase) inhibitor CP-690,550 (CP) achieved ACR70* after 12 weeks, according to the results of a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. The primary outcome for the study was ACR20*, with 75.4% of patients achieving this measure at 12 weeks for both 10mg and 15mg doses.
Health Insurance

Atrial Fibrillation Linked To Increased Hospitalization In Heart Failure Patients

Patients with atrial fibrillation, common in those with advanced chronic heart failure, have an increased risk of hospitalization due to heart failure, according to new research from researchers at the University of Alabama at Birmingham (UAB). The findings, published in June in the European Heart Journal, also suggest that atrial fibrillation is not associated with an increased risk of death in heart failure patients, contradicting previous assumptions. "Our findings show that the presence of atrial fibrillation in heart failure patients did not increase their risk of death, as has been previously suggested, but did increase the risk of hospitalization due to worsening heart failure," said Mustafa Ahmed, M.D., a physician-scientist at the UAB American Board of Internal Medicine Research Pathway Program and the study"s lead investigator. Atrial fibrillation is a condition with irregular heart rhythm and is often accompanied by increased heart rate. "Importantly, atrial fibrillation significantly increased hospitalization due to heart failure only in patients not receiving a beta-blocker or drugs that block the beta-receptors in the heart but not in those receiving a beta-blocker," said Ali Ahmed, M.D., MPH, associate professor in the division of gerontology, geriatrics and palliative care medicine, director of UAB"s Geriatric Heart Failure Clinic and the study"s senior investigator. "In patients with heart failure and atrial fibrillation, beta-blockers, which help reduce heart rate, may be useful in reducing the risk of hospitalization due to worsening heart failure." Ahmed and colleagues matched 487 pairs of heart failure patients with and without atrial fibrillation from the Beta-Blocker Evaluation of Survival Trial. All-cause mortality occurred in 38 percent of the patients with atrial fibrillation against 37 percent of patients without. However, 44 percent patients with atrial fibrillation were hospitalized for worsening heart failure over the course of the trial, against only 38 percent without. The research was supported through a grant from the National Heart, Lung and Blood Institute, one of the National Institutes of Health, and a generous gift from Ms. Jean B. Morris of Birmingham, Alabama. Ahmed"s co-researchers were Mustafa Ahmed, M.D., James Ekundayo, M.D., DrPH, Inmaculada Aban, Ph.D., Bo Liu, MB, MPH, all from UAB; Michel White, MD, Montreal Heart Institute; Thomas Love, Ph.D., Case Western Reserve University; and Wilbert Aronow, MD, New York Medical College. About UAB Health System The UAB Health System includes all of the University of Alabama at Birmingham"s patient care activities, including UAB Hospital, the Callahan Eye Foundation Hospital and The Kirklin Clinic. UAB is the state of Alabama"s largest employer and an internationally renowned research university and academic health center whose professional schools and specialty patient care programs are consistently ranked as among the nation"s top 50. University of Alabama at Birmingham


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009